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Cannabis is a popular drug in Flanders, in spite of the fact that the prevention of its use lists 
high on the Flemish political agenda. The Flemish Government aims to prevent cannabis use 
efficiently and in achieving this, a health economic analysis could be helpful. The possibilities 
and limitations of applying economic evaluation techniques to the prevention of substance 
(ab)use, are discussed in this paper. 
Methods 
A thorough literature search, interviews with key persons, an internet search and an analysis 
of unpublished reports and documents was performed. 
Results 
The interrelation between various forms of substance use, and of the array of strategies to 
prevent this (including the costs thereof), seems to demand a joint evaluation of multiple 
substances. 
Conclusions 
More than methodological difficulties, the general lack of knowledge on age- and time-
specific health and income effects caused by various forms of substance (ab)use, currently 
makes the evidence-based evaluation of prevention of cannabis use in Flanders a virtually 
impossible undertaking. 
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Introduction 
In Europe, cannabis is the most commonly used illegal drug (1). This is also the case in the 
Flemish Region of Belgium. The latest surveys reveal that about one fourth to one third of 
15- to 16-year-old Flemish school students have ever used cannabis (2-4). In Flemish uni-
versity and college students, one out of two has ever used cannabis (5). The lifetime 
experience in the general population is assessed through the ‘National Health Survey’ (6). 
This survey indicates that 12.0% of adults (aged 15 to 64 years) have tried the substance at 
least once (lifetime use). Recent use (in the last 12 months) was reported by 4.6% and use in 
the last month was reported by 2.6% of all adults (aged 15 to 64 years).  
Still, as in most countries, cannabis is illegal in Belgium. In addition, cannabis use can cause 
adverse health effects. Therefore, prevention of drug use in general and cannabis in particu-
lar, lists high on the Belgian political agenda.  
At the federal level, illegal drug (ab)use focuses mainly on legislation and control, i.e. the 
prevention of crime.  
The regions in Belgium (Flanders, Wallonia and Brussels) have autonomy over the choice 
and design of prevention strategies that improve population health. At the Flemish level, 
(drug) prevention policy aims to maximise health gains on the population level. Therefore, 
the Flemish Government stimulates drug prevention workers to use evidence based ap-
proaches. However, interpretation of what constitutes evidence-based prevention is highly 
variable. We define it here as follows: evidence-based prevention means that it can be 
shown to prevent ill health and to improve good health. In the current article, we review how 
such evidence can be compiled and analysed for the optimal prevention of cannabis (ab)use, 
and which evidence is already available. In doing this, the focus is on the possible identifica-
tion of strategies that maximise health gains for a given budget constraint. Therefore, we 
explore the possibilities for health economic evaluations to help making decisions in the area 
of drug prevention.  
Methods 
This article is based on a recent study by the authors (7). Several qualitative research meth-
ods were applied in this study.  
First, a literature review was accomplished. Databases were searched for the following key 
terms: (illicit) drugs, drug (mis)use, drug abuse, substance (mis)use, substance abuse and 
cannabis, in combination with prevention, evidence(-)based, science(-)based, effectiveness, 
(effect)evaluation, cost-effectiveness, health, Belgium and Flanders. The electronic search 
concentrated on the following databases: Medline, PubMed and Sociological Abstracts.  
Second, experts were consulted on (the evaluation of) prevention of cannabis use: semi-
structured interviews were conducted with drug prevention workers, the persons in charge of 
drug prevention programmes and drug prevention experts.  
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Third, we attempted to access the grey literature (unpublished articles and documents).  
Fourth, relevant websites were identified, mainly by using the search engine Google.  
Position in the evidence based debate 
As previously mentioned, interpretation of what constitutes evidence-based prevention of 
drug use is highly variable. This fits into the discussion about evidence-based health promo-
tion, which is made elsewhere (8-14).  
It comes down to the fact that, concerning health promotion, no consensus about ‘evidence’, 
and how to obtain it, exists. Some, in this case the Flemish policy makers, demand epidemi-
ological indicators to demonstrate the effects of health promotion. Effects should be 
expressed in terms of quantitative health outcomes on the population level, e.g. morbidity, 
mortality and quality adjusted life years (QALYs), which are measures frequently used in 
biomedical sciences. However, health promotion workers deem this to be impossible. The 
methods used in biomedical sciences imply that identifiable cause-effect relations are inves-
tigated. Health promotion operates in a complex context, where numerous social, economic, 
political, and cultural factors interact. Therefore, causality generally cannot directly be as-
sessed. Although some alternative methods have been proposed for the health promotion 
field, all of these would need further development in order to be helpful for allocative policy 
decisions. 
The perspective of our paper uses as a starting point the approach of the Flemish Govern-
ment: ‘evidence’ of the effectiveness of drug (ab)use prevention in general and cannabis in 
particular, should be expressed in terms of quantitative health outcomes on the population 
level. We explore here the limits of traditional quantitative analysis for the prevention of can-
nabis, as it is now traditionally used for policy in biomedical sciences.  
What evidence is needed?  
To this day, in Flanders mainly qualitative evaluation research of drug use prevention is ac-
complished. Some evaluative questions that are typically used to do this are given in table 1. 
Table 1: Qualitative evaluation research: some typical questions  
by which drug prevention strategies are currently evaluated 
How was the project accomplished? 
To what extent was the target group actually reached? 
How did the target group experience the intervention?  
Did the project meet the theoretical ideas? 
Is the project still up-to-date?  
… 
Such evaluations are relevant for the programme makers themselves, because they can 
demonstrate why an effect has or has not occurred. However, those studies do not give any 
information about the effects in terms of health gains. Therefore, this kind of research is less 
relevant for the Flemish policy makers: in their opinion no ‘evidence’ is gathered. 
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Potential quantitative health outcomes to express the population effectiveness of interven-
tions against drug (ab)use are: 
 decrease in the number of problem users 
 decrease in the period of time (ab)users remain (ab)users 
 decrease in morbidity related to drug (ab)use 
 decrease in mortality related to drug (ab)use 
Concerning the evaluation of prevention of cannabis (ab)use, mainly 1, 2, and 3 are relevant, 
because this kind of drug use is very unlikely to have an impact on mortality. Note that these 
quantitative outcomes are not independent, because clearly 3 and 4 are influenced by 1 and 
2. Furthermore, 3 and 4 combined can be expressed as increases in Quality Adjusted Life-
Years (QALYs), which has become one of the main expressions of aggregated health out-
comes in economic evaluation. 
More specifically, the information necessary to evaluate the effectiveness of drug use pre-
vention on a population level can be found in table 2.  
Table 2: Data required for health related evaluation of drug use prevention 
Effectiveness of the options for prevention in terms of 
- Reducing the use of drugs 
- Delaying the onset of first use  
- Decreasing the transition from ‘soft’ to ‘hard’ use 
Age and sex specific mortality and morbidity as a consequence of use 
Age specific health effects (morbidity and mortality) as a consequence of (different levels of) use 
- Age and sex specific prevalence and incidence of use 
- Age and sex specific life expectancy, all causes and drug related 
In addition, the information that is needed to expand effectiveness evaluations to health eco-
nomic evaluations (e.g. to estimate cost-effectiveness) is presented in table 3. 
Table 3: Data health economic evaluation of drug use prevention would require, in addition to table 2 
Intervention costs*: direct costs of employees and materials and buildings: 
- Wages of employees and the amount of time spent on the intervention 
- Materials (re-usable/non re-usable, e.g. buildings, transport, didactic material) and attributable costs (dis-
tinguishing between fixed and variable costs)? 
Direct treatment costs*: direct medical costs for treatment of symptomatic (physical and psychical) health prob-
lems related to different levels of use. 
Indirect productivity costs: impact of the different levels of drug use on 
- Absenteeism as a consequence of morbidity 
- Decreasing personal development and level of productivity 
- Unemployment  
Indirect ‘control’ costs 
- repressive and (secondary) preventive means to deal with social trouble (e.g. police activities, social 
workers, prisons,…) 
 linearly related to the number of users 
 non-linearly related to the number of users 
* Absolute minimally required data 
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(Obtain) the evidence 
This section documents what we know, and how we can assess what we don’t know (yet) to 
apply effectiveness and cost-effectiveness analyses to this field.  
Effectiveness of interventions for the prevention of cannabis use  
Current state of the evidence: what do we know? 
Several studies examining the effects of prevention programmes for the prevention of illicit 
substance use are conducted. Many researchers have tried to unite, compare and analyse 
the results of these evaluations in meta-analyses and overviews (15-30). The Health Devel-
opment Agency (HDA – now the National Institute for Health and Clinical Excellence, NICE) 
of the United Kingdom has published an overview of reviews in 2004 (31). Because the 
amount of overviews is expanding, this publication was recently updated (32).  
It is beyond the scope of this article to present the results of all these studies and overviews. 
Only the main conclusions will be outlined. Before doing so, however, some points should be 
noted. First of all, research examining or describing preventive interventions aimed only at 
cannabis use is very scarce, if not absent (33). Besides, there is a general lack of European 
evaluated prevention programmes. Therefore, basically all meta-analyses and overviews of 
prevention programmes draw predominantly on programmes from outside Europe, mainly 
from the US (33-35). Further, school-based preventive interventions have been examined 
most extensively, because most preventive interventions against drug abuse are directed at 
young persons (19, 35-36). Moreover, the effects are mainly expressed in terms of knowl-
edge, attitudes toward drugs and use of drugs. Few studies, if any, examine whether it is 
possible to reduce the number of new cases of problematic drug use (according to the DSM-
IV diagnostic criteria) or whether interventions can prevent hard drug abuse in cannabis us-
ers (37).  
In sum, studies have shown that school-based drug prevention programmes have the poten-
tial to reduce drug use in adolescents. For instance the meta-analysis conducted by Tobler et 
al. (2000) (28) has shown that interactive programmes result in significant reductions of drug 
use, while non-interactive ones do not. Non-interactive programmes are, in contrast to inter-
active programmes, structured, focused on didactic presentations by the teacher and do not 
focus on interactions between students.  
Drug prevention programmes directed at other sectors or target groups have not been sub-
jected to sufficient research to conclude whether they reduce drug (mis)use or not. 
Nevertheless, several interventions directed at other sectors than the school sector seem 
promising and may be able to reduce drug use and misuse (37-38). Clearly, more research is 
needed to document this.  
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General problems encountered in evaluating drug prevention 
There is a lack of European quantitative studies of drug use prevention. This can be ex-
plained by various types of research problems of practical, judicial, ethical and, 
methodological nature. Table 4 presents several examples of these. 
Table 4: Overview of problems encountered for drug prevention evaluations 
Practical problems 
- An intervention can induce different effects when it is implemented in different situations (e.g. different 
schools), because the quality and context of the implementation determines its effectiveness. As a con-
sequence, it is very difficult to estimate the overall effectiveness of preventive interventions. 
- Lack of financial sources 
- Lack of expertise 
- Lack of mandates and orders that encourage effect evaluations 
- … 
Judicial problem 
Cannabis is an illegal drug in most countries, and self-reporting is often the only way to gather information on fre-
quency of (ab)use. The validity of self-reported data may be questionable. 
Ethical problem 
Some methods (e.g. the Randomised Control Trial, RCT), require allocation of subjects to different groups. Some 
persons will be assigned to an experimental group that is exposed to a preventive intervention, whereas others 
will be assigned to the control group that is not exposed to that intervention. Yet, it seems unethical to deny some 
the right of being exposed to an intervention that might be effective in reducing drug use.  
Methodological problems 
An overview of methodological problems encountered in evaluating primary drug prevention, is presented by Uhl 
(1998, 2000). It goes beyond the scope of this article to give an extensive summary. Some of the main aspects 
are:  
- The interest goes primary to long term effects of prevention. However, this kind of research is diffi-
cult to accomplish (amongst other things, there are problems to follow up participants over many 
years). 
- Simultaneous influences: people are confronted with the drug topic in many different ways (e.g. me-
dia, courses, family, friends,…). Because of this, it is nearly impossible to separate intervention 
induced effects from effects caused through other influences.  
- Dependence of observational units: a central, implicit assumption behind many statistical procedures 
is independency of observations. In drug prevention evaluation research it is common that the ob-
servational units are sampled in clusters or groups (e.g. school classes) and treated as independent 




Possibilities for “classic” medical effectiveness evaluation methods 
The problems listed in table 4 indicate that gathering evidence on effectiveness of drug use 
prevention (and particularly for cannabis use) is not easy.  
There are different epidemiological evaluation methods to evaluate drug use prevention. The 
classification of clinical research by Grimes and Schulz (2002) (39) gives a synoptic overview 
of the different types of study design: 
“Clinical research falls into two general categories: experimental and observational, based on 
whether the investigator assigns the exposures or not. Experimental trials can also be subdi-
vided into two: randomised and non-randomised. Observational studies can be either 
analytical or descriptive. Analytical studies feature a comparison (control) group, whereas 
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descriptive studies do not. Within analytical studies, cohort studies track people forward in 
time from exposure to outcome. By contrast, case-control studies work in reverse, tracing 
back from outcome to exposure. Cross-sectional studies are like a snapshot, which meas-
ures both exposure and outcome at one time point. Descriptive studies, such as case-series 
reports, do not have a comparison group. Thus, in this type of study, investigators cannot 
examine associations, a fact often forgotten or ignored”.  
Because the main problems that researchers encounter in evaluating drug prevention are 
already mentioned above and in table 4, attention will only be drawn in short to some addi-
tional problems and possibilities, regardless.  
Experimental studies 
RCT has become the ‘gold standard’ for evidence based medicine (40-41). However, RCTs 
are difficult to accommodate the complexity of drug preventive interventions. Rychetnik et al. 
(2002) (12) postulate that RCTs can be designed to evaluate complex public health interven-
tion, notably cluster RCTs (communities, schools or other clusters are the unit of analysis). 
But even they mention that this kind of research is often not feasible, because of practical or 
resource constraints. As an alternative, a non-randomised controlled trial can be accom-
plished. However, this study design also has some weaknesses, such as a selection bias 
and the fact that it raises ethical questions.  
Observational studies 
To evaluate a drug preventive intervention, a cohort study or a case-control study can be 
planned. For example, if one school implements a specific intervention, and another does 
not, a cohort study can be set up to follow the students of these two schools over several 
years. But, even if differences in drug use between the students of these two schools are 
found, one cannot be sure that this can be attributed to whether the students underwent the 
intervention or not.  
Alternatively, a case-control study could be set up. In short, persons who (have) use(d) can-
nabis need to be found, and matched with persons who have never used cannabis. 
Subsequently, these participants could be questioned retrospectively about factors that may 
have been relevant for their decision to use or not use cannabis (e.g. being exposed to a 
specific drug preventive intervention). This approach also has some weaknesses, such as 
recall bias (depending mainly on how much time has elapsed since influential factors oc-
curred), the existence of unknown decisive factors (which are therefore not part of the 
retrospective questioning), and the fact that the causality of associations cannot be proven.  
(Age and sex specific) Adverse health effects of cannabis use (morbidity and mortality)  
Current state of the evidence: what do we know? 
Here, we will present a brief summary of the known adverse health effects of cannabis use.  
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Concerning probable adverse health effects, there is no known fatal dose of cannabis, and 
no death has ever been attributed solely to the use of cannabis (42). Acute cannabis use can 
induce anxiety and panic, and moreover an acute psychosis (43-46). Additionally, cannabis 
use may cause cognitive and psychomotor impairment, which in turn leads to an increased 
risk of accidental injury or death if an intoxicated person attempts to perform complex tasks 
(e.g. driving a car) (42, 46-49).  
The major adverse effects of chronic use are probably respiratory diseases associated with 
smoking as the method of administration (such as chronic bronchitis and respiratory tract 
cancers) (45-46, 50-51). Individuals with cardiovascular diseases are at an increased risk of 
precipitating or exacerbating the symptoms of their disease (46, 52). Furthermore, it is now 
recognised that cannabis use can lead to cannabis dependence, characterised by an inability 
to abstain from or to control cannabis use (45-46). 
Finally, there is an association between cannabis use and some psychiatric illnesses (such 
as schizophrenia and depression), but whether there are causal relationships is unclear (45-
46, 50).  
Problems encountered in evaluating health effects of cannabis use 
To express the effects of cannabis use prevention in terms of health effects on a population 
level, more knowledge about the adverse health effects of cannabis use is required. Yet, 
there are several factors that contribute to the lack of knowledge. 
First of all, research about the health effects of cannabis is, certainly compared to tobacco, a 
young research area and it takes several decades before the necessary clinical observations 
are available for conclusions to be drawn (46). And long-term research is essential for this 
health issue. 
Second, there are difficulties in quantifying the degree of exposure to cannabis. Related to 
this, it is not (yet) clear to what extent the potency of cannabis (as indexed by ∆9-tetra-
hydrocannabinol (THC) content), contributes to the health effects. It has been claimed re-
cently that the existing medical literature on the health effects underestimates its adverse 
health effects because it was based upon research conducted on less potent forms of can-
nabis than those that are available today. However, at present there is dearth of conclusive 
scientific information about the evolution of THC potency in cannabis over the last two dec-
ades in Europe in general and Flanders in particular, to draw any definite conclusions on this 
matter (53-54). 
Third, there are interpretative problems. Alternative explanations (including other drug use) of 
associations between cannabis use and adverse health outcomes, are difficult to exclude.  
Possibilities for “classic” medical efficacy evaluation methods 
More research is needed to make conclusive judgements about the health effects of canna-
bis use. Can clinical research methods be used to provide the necessary scientific evidence? 
Experimental studies 
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Using RCTs to measure the health effects of cannabis use implicates that the experimental 
group is obliged to use this drug. It may be clear that, because of legal, ethical and practical 
reasons, this is not feasible. One can alternatively accomplish a non-randomised trial. In this 
case, participants choose themselves if they will or will not use cannabis. Yet, a selection 
bias will occur due to this self-selection. Furthermore, only short-term effects can be meas-
ured during the typical follow-up periods in this type of study.  
Observational studies 
On the one hand, to investigate the relation between cannabis use and adverse health ef-
fects in general, a cohort study can be set up. It must be noted, that this will take a long time 
and it needs good follow up of the participants, which will be expensive. Moreover, there can 
be a selection bias because the participants choose themselves if they use cannabis or not. 
On the other hand, in order to investigate if a specific health outcome is caused by cannabis 
use, a case-control study can be undertaken. Patients are then entered into the study based 
on the presence or absence of the disease of interest. These two groups (one with, and one 
without the disease) are then compared to determine if they differ with regard to their expo-
sure to cannabis. This kind of study often requires less time, money, and effort than another 
study design, and still could yield important scientific findings. Yet, case-control studies are 
also more susceptible to biases than other comparative studies (55). To provide useful and 
reliable results, case-control studies must be well designed and carefully executed. The se-
lection of case and control groups, and measurement of exposure information are of great 
importance. Nonetheless, in this context, they seem the most feasible approach. 
Prevalence and incidence of cannabis use 
Age-specific prevalence and incidence of cannabis use can be investigated through cross-
sectional studies (i.e. quantitative surveys on a representative population sample). In many 
countries, including Belgium, the regular national health surveys could collect this informa-
tion. The latest version of this survey (2004) (6) contains several questions on cannabis use 
(life time use, recent use, age at first use, frequency of use), but more aspects of cannabis 
use than only those surveyed at this moment are important (e.g. the amount of cannabis 
used per session/week/month).  
The 2004 survey indicates that, in Flanders, 12.0% of adults (aged 15 to 64 years) have tried 
the substance at least once (lifetime use) and 4.6% reported recent use (in the last 12 
months). Use in the last month was reported by 2.6% of all adults (aged 15 to 64 years). Life 
time use, recent use, use in the last month and frequent use was reported more by males 
than females, and more by the younger than by the older age groups (6).  
Furthermore, surveys about drug use among school populations are common in Belgium. As 
previously mentioned, the latest surveys reveal that about one fourth to one third of 15- to 
16-year-old Flemish school students have ever used cannabis (2-4) and in Flemish university 
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and college students, one out of two has ever used cannabis (5). Cannabis use is more 
common in boys versus girls, and in older versus younger students. 
Until this day, information about prevalence and incidence of cannabis use is only based on 
self-reports. Although the use of cannabis will be admitted easier than the use of so-called 
hard drugs (56), other analytical methods would be more preferable, but due to ethical, legal 
and practical (blood and urine testing for cannabinoids is not yet quite perfect or socially ac-
ceptable) problems, this seems not that feasible today.  
Life expectancy and mortality, all causes and related to cannabis use 
General information about age-specific mortality and life expectancy are readily available 
(e.g. for Belgium, see http://statbel.fgov.be/). The causes of mortality in Belgium can be 
found in the ‘Nationale Databank Mortaliteit’ (National Database Mortality), but caution is 
needed when interpreting this information, due to likely miscoding (57). Besides, the defini-
tion of ‘drug related death’ does not include all deaths caused by drug use. For example, 
deaths caused by lung cancer, which in turn may partially be caused by smoking cannabis, 
are not recognised as drug related. It should be noted again though, that there is no known 
fatal dose of cannabis, and no death has ever been attributed solely to the use of cannabis. 
For these reasons, it is difficult, if not impossible, to express the effects of prevention of can-
nabis use in terms of mortality measurements.  
Intervention costs 
To map out the direct costs of personnel and material, a process evaluation will be neces-
sary (58). In doing so, resource use will fall into two parts, namely volume (time, manpower, 
allocated fixed costs and the like) and price (cost per attributable unit of volume).  
More specifically, the coordinators and/or the staff members of the intervention programme 
should be asked for information about the issues mentioned in table 3, and documents, rele-
vant to the cost structure of these interventions should be studied.  
Considering the nature of most drug prevention interventions, it will be almost impossible to 
assign the prevention costs to one specific drug. It is difficult, if not impossible, to disentangle 
specific prevention efforts of cannabis use from interventions that, among other things, try to 
prevent or reduce cannabis use.  
Direct treatment costs 
Direct treatment costs can be obtained through surveys questioning workers in the health 
care sector and patients, and probably also in several databases (e.g. databases of the 
Rijksinstituut voor ziekte- en invaliditeitsverzekering [RIZIV, the National Institute for Health 
and Disability Insurance] or the Sickness Funds). However, it needs to be noted that Belgium 
trails behind in making publicly available anonymous information with regard to the costs for 
specific treatments. This arrear is caused by the fragmented character of the Belgian health 
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care sector and the budget administrators, as well as competition between sickness funds, 
which provide (mandatory basic and additional) health insurance (59). 
Indirect productivity costs 
Indirect productivity costs also fall into two parts: the volume and price component. On the 
basis of the average gross labour costs, the price component can be calculated. The volume 
component, however, is more problematic. After all, drug use may not only be associated 
with absenteeism and unemployment, but also with decreasing productivity on the job. This 
kind of information could potentially be obtained in a large case-control study.  
Indirect ‘control’ costs 
On the basis of information about budgets for public safety and crime control, estimates of 
the percentage of social disruptions and troubles caused by drug users (and due to their drug 
use), these costs could be estimated. However, assigning these costs to a specific drug, in 
this case cannabis, will be problematic.  
Conclusion and discussion 
This article outlines which information would be theoretically needed to make an analysis of 
the impact of the prevention of drug use (and specifically cannabis use) in terms of health 
effects and economic costs. The perspective of policy makers (and specifically the Flemish 
Government) was taken as a starting point, because this specific question was actually 
asked by them. Their objective is to allocate available sources effectively and efficiently for 
the prevention of cannabis use. The legitimacy of this question is almost self-evident but the 
provision of science-based answers to its solution is shown here to be far less evident.  
This article indicates the lack of knowledge on different aspects related to this policy ques-
tion. Notably, more information is needed on the adverse health effects of cannabis use, the 
effects of drug prevention in terms of reducing cannabis use, delaying the onset of first use 
and decreasing the transition from ‘soft’ to ‘hard’, the age and sex specific prevalence and 
incidence of use, and different kinds of costs (intervention costs, direct treatment costs, indi-
rect productivity costs and indirect control costs). In fact, also the positive effects of cannabis 
use should be taken into account (e.g. feeling and performing better, not using ‘stronger’ 
drugs). However, many problems hamper gathering all this information. As a consequence, it 
will be very difficult, if not impossible, to ever accomplish a credible health economic evalua-
tion of cannabis prevention. 
Although we wanted to steer away from the evidence-based discussion about drug preven-
tion in particular, and health promotion in general, it seems unavoidable. We can no longer 
hold on to the definition of evidence that is postulated here, namely that the ‘evidence’ of the 
effectiveness of the prevention of drugs in general and cannabis in particular, should be ex-
pressed in terms of quantitative health outcomes on the population level. So, since many of 
the current methodologies seem ill-suited to evaluating cannabis use prevention programmes 
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on the one hand but it is increasingly expected that health economic evaluations are carried 
out on the other hand, innovative, yet rigorous methods of evaluation need to be developed.  
This article is, in fact, a contribution to the evidence-based debate. It shows the difficulties 
that one encounters when the perspective of (Flemish) policy makers is followed. Policy 
makers need to become aware of these difficulties, and need to acquire the perspective of 
most health promotion makers. More specifically, the search for alternative evaluation meth-
ods of health promotion in general, and drug prevention in particular, needs to increase in 
scope and substance. 
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